San Francisco, CA /PRNewswire-iReach/ - Tempo Bioscience Inc ("Tempo"), a biotech startup based in San Francisco, California, announces the launch of its central nervous system (CNS) product line of human cell types for in vitroresearch and development (R&D) and chemical testing. Research needs of neuroscientists and cell biologists have inspired Tempo's CNS line of products whose purpose is to improve cellular technologies and to serve drug discovery needs of scientists worldwide.
Using terminally differentiated human cells and reprogramming technologies, Tempo engineers adult human skin cells into inducible pluripotent stem cells (iPSCs), using proprietary foot-print-free technologies, and further differentiates the cells into specific human cellular lineage types. Tempo's cellular products are also available with its various biosensors which function as reporters of calcium fluctuations in the mitochondria or cytoplasm. These products can be used for applications such as: chemical compound screening, toxicity testing, in vitro human cell modeling, and studies of receptor-mediated calcium signaling pathways.
Tempo's initial CNS product line includes neural progenitor cells, astrocytes, and oligodendrocytes. Astrocytes and neural progenitor cells are also available with Tempo's proprietary mitochondrial calcium biosensor and cytosolic calcium biosensor: TempoMitoTM and TempoCalTM.
About Tempo Bioscience Inc: Founded in 2013, Tempo is a technology development startup. Its patent-pending technologies and products serve as tools for pre-clinical drug discovery, toxicology, and non-animal-based testing for the biotechnology, pharmaceutical, and chemical industries.
For more information on Tempo, go to our home page: <www.tempobioscience.com>. Follow Us on Twitter: @TempoBioscience